Dyslipidemia in Type 2 Diabetes (0767-034)

This study has been terminated.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: October 19, 2007
Last updated: June 11, 2015
Last verified: June 2015

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition Intervention Phase
Diabetes Mellitus, Type II
Drug: MK0767
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 111
Study Start Date: July 2003
Study Completion Date: November 2003
Primary Completion Date: November 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and non-pregnant females
  • Age greater than or equal to 21 years
  • Stop current diabetes therapy (if applicable)
  • Stop current statin therapy (if applicable)

Exclusion Criteria:

  • History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
  • Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
  • Patients requiring treatment with corticosteroids for more than 14 consecutive days
  • Patients taking warfarin or warfarin-like anti-coagulants
  • Patients undergoing surgery within 30 days of Visit 1
  • Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
  • Patients with history of pancreatitis or uncontrolled high blood pressure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00547274

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00547274     History of Changes
Other Study ID Numbers: 0767-034  2007_635  MK-0767-034 
Study First Received: October 19, 2007
Last Updated: June 11, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 25, 2016